现代公司的mCOMBRIAX疫苗获得欧盟批准,可保护50岁以上成年人免受流感和COVID-19的影响. Moderna's mCOMBRIAX vaccine gets EU approval to protect adults 50+ against flu and COVID-19.

现代公司已获得欧洲对mCOMBRIAX的批准,这是第一个保护50岁及以上成年人免受流感和COVID-19疫苗的mRNA疫苗. Moderna has received European approval for mCOMBRIAX, the first mRNA vaccine to protect adults 50 and older against both influenza and COVID-19. 单剂量注射显示与分别疫苗相比,免疫反应不劣或更强,但对于老年人中的一种特定流感菌株没有显著的益处. The single-dose shot demonstrated non-inferior or stronger immune responses compared to separate vaccines, though it showed no significant benefit for one specific flu strain in seniors. 该疫苗将在欧盟范围内提供,预计将于2026-27年流感季推出. The vaccine will be available across the EU and is expected to launch for the 2026-27 flu season.